Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study

G Logroscino, E Beghi, S Zoccolella, R Palagano, A Fraddosio, I L Simone, P Lamberti, V Lepore, L Serlenga, the SLAP registry*

Background: While the incidence of amyotrophic lateral sclerosis (ALS) is similar across the world (range, 1.0 to 2.5/100 000), a latitude gradient from north to south has been observed.

Objective: To determine the incidence of ALS in Puglia, a region of south eastern Italy, and to test the latitude gradient hypothesis comparing the present study with findings in studies conducted with the same design in a northern latitude.

Methods: Puglia (4 086 613 residents in 2001) is the site of a multicentre-multisource prospective population based registry established in 1997. All incident ALS cases during the period 1998–99 were enrolled and followed up. Cases were classified using the first and the revised El Escorial criteria.

Results: During the study period 130 cases were enrolled. The annual crude incidence for ALS in Puglia for the two year period 1998–99 was 1.6/100 000 (95% confidence interval, 1.3 to 1.9). The incidence was higher for men (incidence rate (IR) = 2.1 (1.7 to 2.7) than for women (IR = 1.2 (0.9 to 1.5)) in all age groups, with a male to female ratio of 1.6. For both men and women, the incidence increased through age 75 and declined rapidly afterwards. The mean annual incidence adjusted by age and sex to the 2001 Italian population was 1.7/100 000 (1.4 to 2.0).

Conclusions: ALS incidence is within a narrow range across countries, with a peak between 65 and 75 years and a higher incidence in men. A north to south latitude gradient of ALS incidence is not supported by the results of cohort studies.

Epidemiological studies have shown that ALS is present with similar incidence in every part of the world. The incidence of ALS ranges between 1 and 2.5/100 000 in most studies, with the exception of former clusters in the western Pacific. Nevertheless, a latitude gradient from north to south has been suggested by a comparison of the incidence rates at different latitudes in the USA and Europe. It is not clear if the lower incidence rates reported in the Mediterranean area are real or reflect differences in case ascertainment, case definition, or time trends in the incidence of ALS, because these studies were conducted more than 20 years ago. Two recent European studies, one in Ireland and one in northern Italy, reported similar incidences, using a prospective cohort design and the same case definition employing the first version of the El Escorial criteria.

Our aim in this study was to determine the incidence of ALS in Puglia, a region of south eastern Italy, and to test the latitude gradient hypothesis comparing the present study with the findings of studies conducted with the same design and case definition in northern latitudes.

METHODS

Study population

This study was conducted in Puglia, a region in south eastern Italy with five administrative districts, called provinces. The area covers 19 357 km². The population of the study area was 4 086 613, based on ISTAT data in 2001. This was the most accurate estimate of the reference population at the time of the study. There are 23 neurological units in the region of the survey and only one referral centre for ALS, based in the neurological department, University of Bari.

Case ascertainment

The main source of cases for this study is an ongoing multicentre prospective registry enrolling ALS incident cases, named SLAP (Sclerosi Laterale Amiotrofica – Puglia). The registry was established in 1997 and the case ascertainment began on 1 January 1998. The registry has several sources of information:

- The main source includes all neurological departments located in the area of the study. In each department one neurologist is in charge of recruitment of all newly diagnosed ALS patients for the registry. The neurologists at each centre use a standardised questionnaire with all clinical information necessary for the diagnosis and follow up. Demographics, laboratory findings, and diagnostic electromyography (EMG) are recorded as well. Each form is completed when patient’s consent is obtained. This form is forwarded to the central unit of the registry. All the forms are reviewed by one of us (LS), who confirms the diagnosis and decides whether the patient is to be included in the registry. The forms are reviewed by the clinical committee only if there is a conflicting diagnosis between the site investigator and the clinical principal investigator. The final decision for these diagnoses is made on the clinical case records by the clinical committee of the study.
- AISLA, the lay Italian ALS association, cooperates with the registry.

Abbreviations: ALS, amyotrophic lateral sclerosis; PBP, progressive bulbar palsy; PLS, primary lateral sclerosis; PMA, progressive muscular atrophy; SLAP, Sclerosi Laterale Amiotrofica – Puglia
• The registry is also linked to the hospital discharge diagnosis data bank (HDD-DB), a regional computerised system including the diagnosis of each hospital inpatient in Puglia for administrative purposes. At the end of each year the HDD-DB was searched for diagnosis of motor neurone disease (codes 335.2; International Classification of Diseases, 10 revision (ICD-10-CM)).

• After the introduction of riluzole as a licensed treatment for ALS in Italy in 1996, each patient taking riluzole needs to attend one of the outpatient clinics that distribute riluzole in the region of residency. Therefore it is highly probable that every ALS patient consulted a local neurologist at some point during the course of the disease.

The multisource system of case ascertainment allowed us to have a cross check confirmation of cases through different lists. Using this registry, we identified all residents 18 years of age or older in Puglia diagnosed with ALS in the two year period from 1 January 1998 to 31 December 1999. A subject was considered resident if he was living in the area during the 12 months preceding the onset of the disease.

Diagnostic criteria
The diagnosis of ALS was based on the first version of the El Escorial criteria.7 These criteria require the presence of signs in lower or upper motor neurones, or both, and progressive spread of the signs from one region to another, in the absence of neuroimaging and electrophysiological evidence of other diseases that might explain the clinical features. These criteria distinguish four levels of diagnostic certainty: definite, probable, possible, and suspected ALS. Individuals under the age of 18 were excluded to avoid misclassification of neuroimaging and electrophysiological evidence of other diseases that might explain the clinical features. These criteria require the presence of signs in lower or upper motor neurones, or both, and progressive spread of the signs from one region to another, in the absence of neuroimaging and electrophysiological evidence of other diseases that might explain the clinical features. These criteria distinguish four levels of diagnostic certainty: definite, probable, possible, and suspected ALS. Individuals under the age of 18 were excluded to avoid misclassification of other motor neurone diseases of genetic origin, mimicking ALS. Cases with progressive bulbar palsy (PBP), progressive muscular atrophy (PMA), and primary lateral sclerosis (PLS) were included in the study and were reclassified according to the El Escorial criteria.7 We considered all the diagnostic levels for the calculation of incidence.

All cases that were included in this study had EMG. We used EMG to reclassify cases according to the revised El Escorial criteria.6

Statistical analysis
The denominator for the calculation of the incident rates was the total resident population of Puglia in the year 2001. An incidence rate for the population older than 18 years was also calculated. Crude incidence rates were age and sex adjusted to the 2001 Italian population using direct standardisation.9 10

Confidence limits for incidence were calculated assuming a Poisson distribution.9 Rates were also calculated for each province. A standardised incidence ratio (SIR) was calculated using the ALS incidence in the entire region as the standard.15 Based on this we calculated the number of expected cases in each province and the ratio between observed and expected cases. Ninety five per cent confidence intervals (CI) of the SIR were also calculated.

Comparison with other studies was possible only through data on ages between 45 and 74 years. Standardised rates were calculated using the direct method for this age group with the 1990 US population as standard, because this was the standard used to make comparisons in previous studies.11

RESULTS
During the two year surveillance period, 130 patients meeting eligibility criteria were referred to the SLAP registry (81 male (62.3%) and 49 female (37.6%). Median age at diagnosis was 65.4 for men (range 19 to 80 years) and 64.2 for women (range 28 to 80 years). Ten patients were under 45 years old (7.7%). All cases were reported by the primary sources of case ascertainment. There were only two familial ALS cases (1.5%)

Of the 130 cases, there was one 53 year old man with PBP and with no sign of involvement of the second motor neurone. He was diagnosed three months after the onset of symptoms and became a definite case of ALS after six months of follow up. A 62 year old male patient presented with only upper motor neurone signs in three regions six months after the onset of symptoms. Follow up until the end of 2003 confirmed the lack of lower motor neurone involvement, and the diagnosis of PLS was made. There were 12 cases of PMA, nine male and three female, with a median age of 66.4 years and a median onset to diagnosis interval of 9.2 months. Six of 12 PMA cases became definite ALS cases during follow up, with two died within one year after the diagnosis with only lower motor neurone signs. PLS, PBP, and PMA were included in the study and were classified as suspected or possible ALS according to the first version of the El Escorial criteria.7

The crude annual incidence rate for ALS in Puglia for the two year period 1998 to 1999 was 1.6/100 000 person years (95% CI, 1.3 to 1.9). The incidence rate was higher for men (IR = 2.1 (1.7 to 2.6)) than for women (IR = 1.2 (0.9 to 1.6)) in all age groups, with a male to female ratio of 1.6. This ratio was constant across all age groups. For both men and women, the incidence increased with age but declined markedly after age 75 (fig 1, table 1). The annual incidence, age and sex adjusted to the 2001 Italian population, was 1.7/100 000 person years (95% CI, 1.4 to 2.0).

The incidence rates of ALS in the five provinces are compared in table 2. The incidence rates ranged from 1.26 (Foggia) to 2.3 (Taranto) but the difference was not significant.

We compared our incidence rates with those from other studies for individuals between 45 and 74 years of age, adjusting all the rates to the US 1990 general population. The adjusted incidence rate for the 45 to 74 year age group was 4.1/100 000 person years (95% CI, 3.4 to 5.0): 5.5 for men (95% CI, 4.3 to 6.9) and 2.9 for women (95% CI, 2.1 to 4.0) (table 3).

All cases that were included in this study had an EMG. We used EMG to reclassify cases according to the revised El Escorial criteria.6 Of 45 possible cases, 29 (18 men and 11 women) were reclassified after EMG as probable laboratory supported ALS, while 16 were retained as clinically possible ALS (eight male, eight female). The pool of subjects available for ALS clinical trial drugs was 73 patients (definite + probable) using the first version of El Escorial criteria, and 102 using the revised El Escorial criteria.

DISCUSSION
Our study was conducted in a well defined geographical region in the Mediterranean area, using a prospective cohort design with a population based registry as the primary source of cases and El Escorial criteria for the diagnosis.6 7 These
features allowed us to compare the results of this study with other studies conducted using the same methodology in the USA and Europe. Four studies have been published with a prospective design and with data collected between 1989 and 1996, and two of these used identical criteria for the classification of cases.7

The incidence of ALS in Puglia, south eastern Italy, was slightly lower than reported in other studies conducted over the same period with the same case definition and the same design. The results of this study, conducted in a relatively small geographical area, confirm that the ALS incidence is within a narrow range across several countries when a comparison with previous European studies is made (table 3). A north to south latitude gradient does not explain the small variation of ALS incidence in Europe.

The incidence was higher for men than for women, as in previous studies. This sex difference could reflect underascertainment of ALS among women. This is unlikely because the age incidence curves of the two sexes are of similar shape (fig 1), and the interval between the onset of symptoms and diagnosis was ALS similar in men and women (about nine months). This would be unlikely if the referral process for ALS was different for men and women. An alternative explanation is that the difference in incidence is real. The male to female ratio in this study was lower than in previous studies conducted over a longer period.16

The decline in the older age groups might also reflect underascertainment, as previously suggested.18 The diagnosis may be difficult because of the presence of other diseases affecting the bones, joints, and nervous system. It is less likely that a patient over 80 years of age would be referred to a neurologist than a younger person. Even if an older person is referred to a neurologist, the shorter life expectancy in that age group could result in a less aggressive search for the ALS diagnosis. A door to door population based study might unravel the issue of the decline in ALS incidence in older age groups, but such studies are extremely difficult to conduct because of the low incidence of ALS even among the elderly.

Table 1 Incidence rates of amyotrophic lateral sclerosis in men and women for Puglia, south east Italy (1998 to 1999)

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 to 17</td>
<td>439 604</td>
<td>413 809</td>
</tr>
<tr>
<td>18 to 24</td>
<td>215 316</td>
<td>206 887</td>
</tr>
<tr>
<td>25 to 34</td>
<td>322 393</td>
<td>324 442</td>
</tr>
<tr>
<td>35 to 44</td>
<td>288 315</td>
<td>300 169</td>
</tr>
<tr>
<td>45 to 54</td>
<td>245 347</td>
<td>256 441</td>
</tr>
<tr>
<td>55 to 64</td>
<td>203 593</td>
<td>220 803</td>
</tr>
<tr>
<td>65 to 74</td>
<td>164 781</td>
<td>201 017</td>
</tr>
<tr>
<td>75 to 84</td>
<td>79 262</td>
<td>118 917</td>
</tr>
<tr>
<td>85+</td>
<td>22 282</td>
<td>44 230</td>
</tr>
</tbody>
</table>

Crude IR 1 998 893 | 2 096 715 |

<table>
<thead>
<tr>
<th>Male</th>
<th>Population</th>
<th>Cases</th>
<th>Rate</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>439 604</td>
<td>0</td>
<td>0</td>
<td>--</td>
</tr>
<tr>
<td>18</td>
<td>215 316</td>
<td>0</td>
<td>0</td>
<td>--</td>
</tr>
<tr>
<td>25</td>
<td>322 393</td>
<td>0</td>
<td>0</td>
<td>--</td>
</tr>
<tr>
<td>35</td>
<td>288 315</td>
<td>3</td>
<td>0.5</td>
<td>0.16 to 1.6</td>
</tr>
<tr>
<td>45</td>
<td>245 347</td>
<td>11</td>
<td>2.24</td>
<td>1.18 to 4.04</td>
</tr>
<tr>
<td>55</td>
<td>203 593</td>
<td>22</td>
<td>5.4</td>
<td>3.55 to 8.20</td>
</tr>
<tr>
<td>65</td>
<td>164 781</td>
<td>35</td>
<td>10.6</td>
<td>7.61 to 14.76</td>
</tr>
<tr>
<td>75</td>
<td>79 262</td>
<td>9</td>
<td>5.67</td>
<td>2.95 to 10.90</td>
</tr>
<tr>
<td>85+</td>
<td>22 282</td>
<td>0</td>
<td>0</td>
<td>--</td>
</tr>
<tr>
<td>0 to 17</td>
<td>1 998 893</td>
<td>81</td>
<td>2.1</td>
<td>1.69 to 2.61</td>
</tr>
</tbody>
</table>

Among individuals over 18 years, the average incidence rate was 2.6 (95% CI, 2.1 to 3.2) in men and 1.5 (0.9 to 2.6) in women.

Table 2 Crude and age and sex-adjusted incidence mean annual rate by province of residence

<table>
<thead>
<tr>
<th>Province</th>
<th>Population</th>
<th>Observed cases</th>
<th>Crude IR/10^6</th>
<th>Expected cases*</th>
<th>Standardised incidence ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bari</td>
<td>1 560 520</td>
<td>47</td>
<td>1.51</td>
<td>49.6</td>
<td>0.95</td>
<td>0.7 to 1.2</td>
</tr>
<tr>
<td>Foggia</td>
<td>697 402</td>
<td>17</td>
<td>1.22</td>
<td>22.2</td>
<td>0.77</td>
<td>0.4 to 1.1</td>
</tr>
<tr>
<td>Taranto</td>
<td>586 972</td>
<td>27</td>
<td>2.30</td>
<td>18.7</td>
<td>1.44</td>
<td>0.9 to 3.0</td>
</tr>
<tr>
<td>Brindisi</td>
<td>411 051</td>
<td>11</td>
<td>1.34</td>
<td>13.1</td>
<td>0.84</td>
<td>0.4 to 1.4</td>
</tr>
<tr>
<td>Lecce</td>
<td>815 685</td>
<td>28</td>
<td>1.71</td>
<td>25.9</td>
<td>1.08</td>
<td>0.7 to 1.4</td>
</tr>
<tr>
<td>Puglia</td>
<td>4 086 761</td>
<td>130</td>
<td>1.59</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Based on the crude incidence rate of Puglia.

www.jnnp.com
We included all four diagnostic levels of the first version of El Escorial, including PLS and PMA, in the calculation of the incidence rates. These diagnostic categories were included in the Scottish and the Irish studies but not in the one conducted in Piemonte. The number of cases of PMA was particularly high in our series—about eight times higher than reported in the Irish study. Two individuals died without signs of upper neurone involvement and six became definite ALS. There are several pieces of evidence showing that most patients with PMA (suspect ALS) evolve to typical ALS. About 10% of those who die from ALS are still classified as suspected or possible according to the El Escorial criteria. The involvement of the pyramidal tracts has been shown in necropsy series of PMA or suspect ALS cases. Thus the identification of cases of suspected ALS and their inclusion in ALS epidemiological studies is important for describing the whole spectrum of this clinically heterogeneous disease.

In this population based setting, the use of the revised El Escorial criteria increased the pool of ALS patients available for clinical trials by almost 30%. We did not observe a significant regional variation in incidence. Regional variations were found in some of the previous studies but not in others.

The main strength of our study is that complete case ascertainment is highly probable owing to the multisource system used for the identification of the ALS cases from a stable reference population living in a well defined geographical area. Nevertheless, some atypical or very elderly cases who either did not receive any medical attention or were improperly diagnosed could have been missed.

Conclusions

This study, conducted in the Mediterranean region, supports previous work suggesting that ALS is age related, commoner in men, and has the same incidence in different geographical areas. The even incidence rates across populations opposes the view that environmental risk factors play a major role in causation of ALS. An alternative explanation is that diffuse environmental risk factors for ALS are present homogeneously at different latitudes in Europe. In a population based setting, both case–control and cohort studies are often unable to detect risk factors with insufficient heterogeneity because of lack of power. If this is the case, to further clarify the role of environmental factors, a possible strategy could be to conduct collaborative analytical studies with incident cases. A collaborative project of population based ALS registries (EURALS) is being implemented in Europe and will provide the basis for this type of study.

ACKNOWLEDGEMENTS

We own a particular thank to Mr Camillo Colapinto who was the first to launch the idea of a regional registry for ALS in Puglia and always gave us a great support of enthusiasm and new ideas both in person and through the AILSA.

Table 3  Incidence of ALS in men and women 45 to 74 years old by latitude gradient in selected studies in Europe which used a prospective cohort design, age adjusted to the 1990 US population

<table>
<thead>
<tr>
<th>Country</th>
<th>Years</th>
<th>Latitude (°)</th>
<th>IR men</th>
<th>IR women</th>
<th>Combined IR</th>
<th>95% CI IR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scotland</td>
<td>1989</td>
<td>55 to 59</td>
<td>6.7</td>
<td>3.8</td>
<td>5.2</td>
<td>4.1 to 6.4</td>
</tr>
<tr>
<td>Ireland</td>
<td>1993 to 1997</td>
<td>52 to 55</td>
<td>6.7</td>
<td>5.3</td>
<td>6.0</td>
<td>5.1 to 6.9</td>
</tr>
<tr>
<td>Piemonte (Italy)</td>
<td>1993 to 1996</td>
<td>44 to 46</td>
<td>5.9</td>
<td>4.7</td>
<td>5.4</td>
<td>4.6 to 6.3</td>
</tr>
<tr>
<td>Puglia (Italy)</td>
<td>1998 to 1999</td>
<td>40 to 42</td>
<td>5.5</td>
<td>2.9</td>
<td>4.1</td>
<td>2.6 to 5.7</td>
</tr>
</tbody>
</table>

CI, confidence interval; IR, incidence rate.

E Beghi, Istituto Ricerche Farmacologiche Mario Negri, Milan, Italy
S Zoccocella, R Palagano, A Fraddosio, I L Simone, P Lambert, V Lepore, Department of Neurological Sciences, University of Bari, Bari, Italy
L Serlenga, Operating Unit of Neurology, Andria (BA), Italy

Competing interests: none declared

APPENDIX

Sclerosis Laterale Amiotrofica – Puglia (SLAP Registry)
Principal investigators: Giancarlo Logroscino (Boston); Luigi Selenga (Andria)
Scientific committee: Ettore Beghi, Vito Lepore, Paulo Livrea, Giancarlo Logroscino, Isabella L Simone, Luigi Serlenga
Clinical committee: Paolo Lambert, Bruno Maggio, Bruno Passarella, Vito Santamato, Luigi Serlenga, Isabella Simone, Pasquale Simone, Franco Valluzzi
Epidemiologic and Data Management Unit: Vito Lepore, Saverio Staffieri
Study monitors: Angela Fraddosio, Rino Palagano, Stefano Zoccolella.
SLAP neurologists: Giuseppe Belfiore (Lecce), Giuseppe Benedetto (Noci), Nicola Cacudi (S Paolo, Bari), Antonio Cazzato (Lecce), Pasquale Colamartino (Bisceglie), Pietro Di Viesti (S Giovanni Rotondo), Silvana Epifani (Galatina), Francesco Linscesso (Taranto) Bruno Maggio (Conversano), Vincenzo Montillo (Cassano Murge), Angelo Moramarco (Altamura), Antonello Nicolaci (Scorrano), Cecilia Nozzoli (Brindisi), Sergio Pasca (Casarano), Rosaria Pulimeno (Gallipoli), Giuseppe Russo (Grottaglie), Vito Santamato (DiVenere, Bari), Isabella Laura Simone (Policlinico, Bari), Giovanni Strafella (Andria), Maria Terraciano (Foggia), Paolo Tota (Barletta), Francesco Valluzzi (Putignano).

REFERENCES


www.jnnp.com
Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. Clinical Evidence needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

Areas for which we are currently seeking authors:
- Child health: nocturnal enuresis
- Eye disorders: bacterial conjunctivitis
- Male health: prostate cancer (metastatic)
- Women’s health: pre-menstrual syndrome; pyelonephritis in non-pregnant women

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:
- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500-3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with Clinical Evidence editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every six months using any new, sound evidence that becomes available.

The Clinical Evidence in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.
- To expand the topic to include a new question about once every 12–18 months.
- If you would like to become a contributor for Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Klara Brunnhuber (kbrunnhuber@bmjgroup.com).

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for Clinical Evidence, please complete the peer review questionnaire at www.clinicalevidence.com or contact Klara Brunnhuber (kbrunnhuber@bmjgroup.com).
Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study

G Logroscino, E Beghi, S Zoccolella, R Palagano, A Fraddosio, I L Simone, P Lamberti, V Lepore and L Serlenga

*J Neurol Neurosurg Psychiatry* 2005 76: 1094-1098
doi: 10.1136/jnnp.2004.039180

Updated information and services can be found at:
http://jnnp.bmj.com/content/76/8/1094

These include:

References
This article cites 18 articles, 11 of which you can access for free at:
http://jnnp.bmj.com/content/76/8/1094#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Motor neurone disease (302)
- Neuromuscular disease (1311)
- Spinal cord (542)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/